GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

maridebart cafraglutide   Click here for help

GtoPdb Ligand ID: 13316

Synonyms: AMG 133 [4] | AMG-133 | AMG133 | MariTide
Compound class: Antibody
Comment: Maridebart cafraglutide (AMG133) is an anti-human gastric inhibitory polypeptide receptor (GIPR) antagonist antibody-peptide conjugate [1,4]. It has two attached glucagon-like peptide 1 (GLP-1) agonist peptides (cafraglutide). Maridebart cafraglutide is proposed to ellicit synergistic effects (antagonism of GIPR signalling and activation of GLP-1 receptor signalling) to regulate body weight for application as an anti-obesity modality [3-4].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Bailey CJ, Flatt PR, Conlon JM. (2023)
An update on peptide-based therapies for type 2 diabetes and obesity.
Peptides, 161: 170939. [PMID:36608818]
2. Jastreboff AM, Ryan DH, Bays HE, Ebeking PR, Mackowski MG, Philipose N, Ross L, Liu Y, Burns CE, Abbasi SA et al.. (2025)
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial.
NEJM, Epub ahead of print. DOI: 10.1056/NEJMoa25042
3. Killion EA, Wang J, Yie J, Shi SD, Bates D, Min X, Komorowski R, Hager T, Deng L, Atangan L et al.. (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Sci Transl Med, 10 (472). [PMID:30567927]
4. Véniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA et al.. (2024)
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings.
Nat Metab, 6 (2): 290-303. [PMID:38316982]